Atossa Genetics to Present at the Sachs Associates Cancer Bio Partnering Forum and Participate on the Cancer Tech Panel
(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 05/14/13 -- (NASDAQ: ATOS), The Breast Health Company™, announced today that Dr. Steven Quay, Chairman, CEO & President, will speak and participate on the Diagnostics panel at the on Wednesday, May 22, 2013, at the Westin Copley Place in Boston, Massachusetts. Dr. Quay's corporate presentation will take place from 11:00 a.m. to 11:15 a.m. and the Diagnostics panel will take place from 11:55 a.m. to 12:25 p.m. Eastern Time.
Dr. Quay commented, "The Sachs Associates Cancer Bio Partnering Forum is a unique event that brings together a prestigious group of thought leaders and business development executives in the cancer biology space to discuss the latest advances in cancer diagnosis and treatments. I appreciate the opportunity to present our and other and to discussing our plans to develop an intraductal therapy for treatment of in order to prevent breast cancer. I look forward to a highly productive meeting."
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented and patented laboratory developed tests (LDT) that can detect up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
, a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA. The NRLBH provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the , and the , a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating breast cancer cells and a tailored treatment plan for patients and their caregivers.
For additional information, please visit . You can also view a video about the ForeCYTE test here: .
This press release is being issued for compliance with Regulation FD. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics, Inc.
Kyle Guse
CFO and General Counsel
800-351-3902
Matthew D. Haines
MBS Value Partners
212-710-9686
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.05.2013 - 06:30 Uhr
Sprache: Deutsch
News-ID 1226935
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SEATTLE, WA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 305 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Atossa Genetics to Present at the Sachs Associates Cancer Bio Partnering Forum and Participate on the Cancer Tech Panel
"
steht unter der journalistisch-redaktionellen Verantwortung von
Atossa Genetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
